Tatva Chintan Pharma Chem Limited has informed the Exchange about Investor Presentation
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tatva Chintan Pharma Chem reported FY25 revenue of ₹3,827 crore, down about 3% YoY, with EBITDA plunging nearly 50% to ₹342 crore and margins compressing sharply to 8.9% from 17.3% in FY24. Profit after tax fell 81% to ₹57 crore, with EPS dropping to ₹2.44 from ₹13.26. Q4FY25 showed a 10% YoY revenue increase to ₹1,079 crore but EBITDA still declined 43% YoY to ₹90 crore. The CMD attributed the weak performance to subdued export demand, inventory destocking, and geopolitical headwinds, but guided that FY26 will be a turnaround year with over 25% topline growth and meaningful improvement in EBITDA margins, supported by new product commercialisation and better capacity utilisation.
Despite a sharp decline in FY25 profitability, the management's optimistic FY26 guidance on topline growth of 25%+ and EBITDA margin recovery could lift sentiment, though execution risks remain given the steep year-on-year earnings fall and the negative outlook on the company's CRISIL credit rating.